Seeking Alpha analysts discuss the outlook for Big Pharma M&A, citing patent cliffs and revenue declines as key drivers. Bristol Myers Squibb's rumored merger talks with AstraZeneca highlight industry activity. Analysts predict increased focus on late-stage assets in oncology, neuroscience, and rare diseases, with potential targets including Krystal Biotech, TG Therapeutics, and Abivax to address loss of exclusivity.